Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

被引：23
|
作者：
Moskowitz, Alison J. [1 ]
Advani, Ranjana H. [2 ]
Bartlett, Nancy L. [3 ]
Vose, Julie M. [4 ]
Ramchandren, Radhakrishnan [5 ]
Feldman, Tatyana A. [6 ]
LaCasce, Ann S. [7 ]
Christian, Beth A. [8 ]
Ansell, Stephen M. [9 ]
Moskowitz, Craig H. [10 ]
Brown, Lisa [11 ]
Taft, David [11 ]
Ansari, Sahar [11 ]
Zak, Daniel E. [11 ]
Sacchi, Mariana [12 ]
Manley, Thomas [11 ]
Herrera, Alex F. [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA
[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] James Canc Hosp, Columbus, OH USA
[9] Mayo Clin, Rochester, MN USA
[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[11] Seattle Genet Inc, Bothell, WA USA
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122576
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
238
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
    Advani, Ranjana
    Oki, Yasuhiro
    Shustov, Andrei R.
    Grove, Laurie E.
    Bartlett, Nancy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Klasa, Richard
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Younes, Anas
    BLOOD, 2010, 116 (21) : 128 - 129
  • [23] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN plus AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
    Lee, Hun Ju
    Flinn, Ian W.
    Melear, Jason
    Ramchandren, Rod
    Friedman, Judah
    Burke, John M.
    Linhares, Yuliya
    Peterson, Matthew R.
    Raval, Mihir
    Chintapatla, Rangaswamy
    Feldman, Tatyana A.
    Yimer, Habte
    MiguelIslas-Ohlmayer
    Dean, Asad
    Rana, Vishal
    Gandhi, Mitul D.
    Renshaw, John
    Gillespie-Twardy, Amanda L.
    Ho, Linda
    Fanale, Michelle A.
    Guo, Wenchuan
    Yasenchak, Christopher A.
    BLOOD, 2021, 138
  • [25] Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Chen, Lu
    Herrera, Alex F.
    Mei, Matthew
    McBride, Katrina
    Abary, Rosie
    Siddiqi, Tanya
    Popplewell, Leslie
    Forman, Stephen J.
    Rosen, Steven T.
    Kwak, Larry W.
    BLOOD, 2018, 132
  • [26] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Giaccone, L.
    Festuccia, M.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Boccadoro, M.
    Vitolo, U.
    Mordini, N.
    Pini, M.
    Busca, A.
    Bruno, B.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1208 - 1211
  • [27] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    L Giaccone
    M Festuccia
    F Zallio
    R Sorasio
    L Brunello
    E Maffini
    C Dellacasa
    R Passera
    G Iovino
    S Aydin
    M Boccadoro
    U Vitolo
    N Mordini
    M Pini
    A Busca
    B Bruno
    Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
  • [28] Long-Term Follow-Up of Brentuximab Vedotin +/- Dacarbazine as First-Line Therapy in Elderly Patients With Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 18 - 19
  • [29] Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.
    Friedberg, Jonathan W.
    Forero-Torres, Andres
    Holkova, Beata
    Goldschmidt, Jerome H.
    Boccia, Ralph V.
    Bordoni, Rodolfo
    Cline, Vivian Jean M.
    Patel-Donnelly, Dipti
    Flynn, Patrick J.
    Olsen, Gregg A.
    Chen, Robert W.
    Galderisi, Faith
    Wang, Yinghui
    Sharman, Jeff Porter
    Yasenchak, Christopher A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
    Diefenbach, Catherine S.
    Hong, Fangxin
    Ambinder, Richard F.
    Cohen, Jonathan B.
    Robertson, Michael J.
    David, Kevin A.
    Advani, Ranjana H.
    Fenske, Timothy S.
    Barta, Stefan K.
    Palmisiano, Neil D.
    Svoboda, Jakob
    Morgan, David S.
    Karmali, Reem
    Sharon, Elad
    Streicher, Howard
    Kahl, Brad S.
    Ansell, Stephen M.
    LANCET HAEMATOLOGY, 2020, 7 (09): : E660 - E670
12345